Aptus Clinical and the Cell and Gene Therapy Catapult Announce Their Clinical Service Partnership
CRO Aptus Clinical has been appointed as a supplier for clinical services by the Cell and Gene Therapy Catapult (CGTC). As an early-phase CRO, its role is to support development and delivery of advanced therapy studies in the UK and Europe. Through this partnership, Aptus Clinical will primarily provide dedicated site set-up and monitoring of investigational sites for the CGTC’s collaborators.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025